Newsbenzinga
AIM ImmunoTech Says Phase 2 DURIPANC Topline Results Expected In Q1 2027, With Additional Clinical And Immune-Response Analyses Anticipated In Q3 2027
· Published
Article summary
Please check the source for details.
An excerpt from the original article.Related companies
Analyzed by WAPE AI.
Preparing English content…
Comments —
Loading comments…